Adoptive cell therapies for glioblastoma

Frontiers in Oncology

Volumn 3 NOV, Issue , 2013, Pages

  Bielamowicz, Kevin ^a,b   Khawja, Shumaila ^b   Ahmed, Nabil ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cell therapies; GBM; Immunotherapy

Indexed keywords

BETA INTERFERON; CD133 ANTIGEN; EPHRIN A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 13; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; GAMMA DELTA T LYMPHOCYTE; GLIOBLASTOMA; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR INVASION;

EID: 84891051882     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00275     Document Type: Review

References (110)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352(10):987-96. doi: 10.1056/NEJMoa043330
2. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science (2004) 305:200-5. doi:10.1126/science.1100369
3. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2005) 54(3):187-207. doi:10.1007/s00262-004-0560-6
4. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest (2004) 113(11):1515-25. doi:10.1172/JCI21926
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature (1998) 392:245-52. doi:10.1038/32588
6. Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins (2011). p. 431-2.
7. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 117(6):1466-76. doi:10.1172/JCI32446
8. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 331(6024):1565-70. doi:10.1126/science.1203486
9. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol (2007) 25:243-65. doi:10.1146/annurev.immunol.25.022106.141527
10. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther (2013). doi:10.1038/mt.2013.185
11. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res (2007) 13(2 Pt 1):566-75. doi:10.1158/1078-0432.CCR-06-1576
12. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 102(16):5814-9. doi:10.1073/pnas.0402870102
13. Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol (2006) 79(1):61-5. doi:10.1007/s11060-005-9116-7
14. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 16(3):800-13. doi:10.1158/1078-0432.CCR-09-2730
15. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 63:5821-8.
16. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 444(7120):756-60. doi:10.1038/nature05236
17. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 9(1):67-78. doi:10.1158/1535-7163.MCT-09-0734
18. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res (2010) 16(2):461-73. doi:10.1158/1078-0432.CCR-09-1983
19. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 12(11):1113-25. doi:10.1093/neuonc/noq082
20. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys (2005) 62(5):1423-6. doi:10.1016/j.ijrobp.2004.12.085
21. Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res (2011) 17(16):5473-80. doi:10.1158/1078-0432.CCR-11-0774
22. Boskovitz A, Wikstrand CJ, Kuan C-T, Zalutsky MR, Reardon DA, Bigner DD. Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther (2004) 4:1453-71. doi:10.1517/14712598.4.9.1453
23. Combs SE, Heeger S, Haselmann R, Edler L, Debus J, Schulz-Ertner D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-phase I/II trial: study protocol. BMC Cancer (2006) 6:133. doi:10.1186/1471-2407-6-133
24. Marras C, Mendola C, Legnani FG, DiMeco F. Immunotherapy and biologic modifiers for the treatment of malignant brain tumors. Curr Opin Oncol (2003) 15:204-8. doi:10.1097/00001622-200305000-00004
25. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res (2000) 6:2209-18.
26. Tsuboi K, Saijom K, Ishikawa E, Tsurushima H, Takano S, Morishita Y, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res (2003) 9:3294-302.
27. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sorensen M, Kosteljanetz M, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol (2010) 12(5):508-16. doi:10.1093/neuonc/nop063
28. Gajadhar AS, Bogdanovic E, Munoz DM, Guha A. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol Cancer Res (2012) 10(3):428-40. doi:10.1158/1541-7786.MCR-11-0531
29. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol (2001) 29:1157-68. doi:10.1016/S0301-472X(01)00696-8
30. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol (2013) 132(3):536-44. doi:10.1016/j.jaci.2013.07.006
31. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant (2003) 32(2):177-86. doi:10.1038/sj.bmt.1704086
32. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res (2004) 24:1861-72.
33. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol (1999) 100:216-32. doi:10.1016/S0165-5728(99)00203-9
34. Alvarez-Breckenridge CA, Yu J, Caligiuri MA, Chiocca EA. Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology (2013) 2(4):e23658. doi:10.4161/onci.23658
35. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105(8):3051-7. doi:10.1182/blood-2004-07-2974
36. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer (1995) 76(5):840-52. doi:10.1002/1097-0142(19950901)76:5<840::AID-CNCR2820760519>3.0.CO;2-R
37. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother (2009) 32(9):914-9. doi:10.1097/CJI.0b013e3181b2910f
38. Komatsu F, Kajiwara M. CD18/CD54, CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG. Oncol Res (2000) 12:17-24.
39. Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, Meleth S, et al. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol (2009) 11(4):357-67. doi:10.1215/15228517-2008-111
40. Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, et al. Preclinical evaluation of ex vivo expanded/activated gammadelta T cells for immunotherapy of glioblastoma multiforme. J Neurooncol (2011) 101(2):179-88. doi:10.1007/s11060-010-0245-2
41. Collins J, Robert H, Shpilberg O, Drobyski WR, Porter DL, Giralt S, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 15(2):433-44.
42. Hasskarl J, Zerweck A, Wasch R, Ihorst G, Bertz H, Finke J. Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft. Bone Marrow Transplant (2012) 47(2):277-82. doi:10.1038/bmt.2011.45
43. Huang X-J, Liu D-H, Liu K-Y, Xu L-P, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica (2007) 92:414-7. doi:10.3324/haematol.10570
44. Alyea EP, Canning C, Neuberg D, Daley H, Houde H, Giralt S, et al. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant (2004) 34(2):123-8. doi:10.1038/sj.bmt.1704536
45. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive T cell therapy. N Engl J Med (2011) 365(18):1673-83. doi:10.1056/NEJMoa1106152
46. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 108(6):1797-808. doi:10.1182/blood-2006-02-001909
47. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB, et al. Characterization of an established human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In vitro Cell Dev Biol (1992) 28A(9-10):609-14. doi:10.1007/BF02631035
48. Lampson LA. Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Microsc Res Tech (1995) 32(4):267-85. doi:10.1002/jemt.1070320402
49. Miescher S, Whiteside TL, de Tribolet N, von Fleidner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg (1988) 68:438-48. doi:10.3171/jns.1988.68.3.0438
50. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin 2. Cancer Immunol Immunother (1997) 45:77-87. doi:10.1007/s002620050405
51. Quattrocchi KB, Miller CH, Smith M, Gudeman S, Cush S, Varia MA. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol (1999) 45:141-57. doi:10.1023/A:1006293606710
52. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 26(32):5233-9. doi:10.1200/JCO.2008.16.5449
53. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg (1998) 89:42-51. doi:10.3171/jns.1998.89.1.0042
54. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res (2010) 16(19):4892-8. doi:10.1158/1078-0432.CCR-10-1507
55. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 26(4):332-42. doi:10.1097/00002371-200307000-00005
56. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol (1991) 147:729-37.
57. Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, et al. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol (1994) 152:1277-88.
58. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 25:587-617. doi:10.1146/annurev.immunol.25.022106.141553
59. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 345:9-13. doi:10.1016/S0140-6736(95)91150-2
60. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 110(8):2838-45. doi:10.1182/blood-2007-05-091280
61. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood (2005) 105:1898-904. doi:10.1182/blood-2004-07-2975
62. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 62(12):3347-50.
63. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2008) 10(1):10-8. doi:10.1215/15228517-2007-035
64. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol (2008) 116(1):79-86. doi:10.1007/s00401-008-0359-1
65. Ghazi A, Ashoori A, Heslop HE, Hanley PJ, Leen AM, Brawley VS, et al. Generation of polyclonal CMV-specific T Cells for the adoptive immunotherapy of glioblastoma. J Immunother (2012) 35:159-68. doi:10.1097/CJI.0b013e318247642f
66. Ahmed N. Administration of CMV-specific cytotoxic T cells in patients with glioblastoma multiforme (COGLI). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) (2010-2013). Available from: http://clinicaltrials.gov/ct2/show/NCT01205334?term=cogli&rank=1
67. Ahmed N. CMV-specific cytotoxic T lymphocytes expressing CAR targeting HER2 in patients with GBM (HERT-GBM). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) (2010-2013). Available from: http://clinicaltrials.gov/ct2/show/NCT01109095?term=HERT-GBM&rank=1
68. Hua W, Yao Y, Chu Y, Zhong P, Sheng X, Xiao B, et al. The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. J Neurooncol (2011) 105(2):149-57. doi:10.1007/s11060-011-0572-y
69. Qin K, Tian G, Li P, Chen Q, Zhang R, Ke YQ, et al. Anti-glioma response of autologous T cells stimulated by autologous dendritic cells electrofused with CD133+ or CD133-glioma cells. J Neuroimmunol (2012) 242(1-2):9-15. doi:10.1016/j.jneuroim.2011.11.001
70. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 368(16):1509-18. doi:10.1056/NEJMoa1215134
71. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 118:6050-6. doi:10.1182/blood-2011-05-354449
72. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods (2001) 248:67-76. doi:10.1016/S0022-1759(00)00343-4
73. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell. Proc Natl Acad Sci U S A (1993) 90:720-4. doi:10.1073/pnas.90.2.720
74. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 3(1):35-45. doi:10.1038/nrc971
75. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy (2003) 5(3):211-26. doi:10.1080/14653240310001488
76. Wang L-F, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep (2008) 19:151-6.
77. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res (2004) 64:4980-6. doi:10.1158/0008-5472.CAN-03-3504
78. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res (2007) 67(17):7983-6. doi:10.1158/0008-5472.CAN-07-1493
79. Forman S. Cellular adoptive immunotherapy using genetically modified T-lymphocytes in treating patients with recurrent or refractory high-grade malignant glioma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) (2008-2011). Available from: http://clinicaltrials.gov/ct2/show/NCT00730613?term=glioma+and+forman&rank=1
80. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res (2010) 16(2):474-85. doi:10.1158/1078-0432.CCR-09-1322
81. Kahlonn KS, Brown C, Cooper LJN, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res (2004) 64:9160-6. doi:10.1158/0008-5472.CAN-04-0454
82. Rosenberg SA. A phase I/II study of the safety and feasibility of administering T cells expressing anti-EGFRvIII chimeric antigen receptor to patients with malignant gliomas expressing EGFRvIII. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) (2011-2013). Available from: http://clinicaltrials.gov/ct2/show/NCT01454596?term=EGFRvIII&rank=3
83. Kagamu H, Shu S. Purification of L-selectin low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol (1998) 160:3444-52.
84. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 8(3):234-43. doi:10.1215/15228517-2006-006
85. Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 3(4):e1983. doi:10.1371/journal.pone.0001983
86. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 188:287-96. doi:10.1084/jem.188.2.287
87. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 66(6):3294-302. doi:10.1158/0008-5472.CAN-05-3773
88. Zheng P, Guo Y, Niu Q, Levy DE, Dyck JA, Lu S, et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature (1998) 396:373-6. doi:10.1038/24628
89. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer Res (1998) 58:2149-57.
90. Liu J-Q, Bai X-F. Overcoming immune evasion in T cell therapy of cancer: lessons from animal models. Curr Mol Med (2008) 8:68-75. doi:10.2174/156652408783565531
91. Byrd T, Grossman RG, Ahmed N. Medulloblastoma-biology and microenvironment: a review. Pediatr Hematol Oncol (2012) 6:495-506. doi:10.3109/08880018.2012.698372
92. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T Cell activation by CD4+CD25+ immunoregulatory cells. J Immunol (2001) 167:1137-40.
93. Sao N, Hayakawa S, Takagawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4+ T-regulatory cells and systemic collapse of antitumour immunity. Immunology (2001) 104:449-57. doi:10.1046/j.1365-2567.2001.01279.x
94. Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother (2002) 25(3):207-17. doi:10.1097/00002371-200205000-00003
95. Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual blood-brain barrier disruption consortium meeting. Clin Cancer Res (2005) 11:421-8.
96. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2010) 115:925-35. doi:10.1182/blood-2009-08-239186
97. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood (2010) 116(23):5045-9. doi:10.1182/blood-2010-04-281873
98. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood (2012) 119(11):2644-56. doi:10.1182/blood-2011-08-371971
99. Salsman VS, Chow KK, Shaffer DR, Kadikoy H, Li X-N, Gerken C, et al. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One (2011) 6(5):e20267. doi:10.1371/journal.pone.0020267
100. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res (2009) 15(12):3918-26. doi:10.1158/1078-0432.CCR-08-2788
101. Kanno H, Sato H, Yokoyama T-A, Yoshizumi T, Yamada S. The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway. Int J Oncol (2013) 42(3):881-6. doi:10.3892/ijo.2013.1773
102. Zhang M, Kleber S, Rohrich M, Timke C, Han N, Tuettenberg J, et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res (2011) 71(23):7155-67. doi:10.1158/0008-5472.CAN-11-1212
103. Foster AE, Heslop HE, Dotti G, Lu A, Khalil M, Brenner MK, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother (2008) 31:500-5. doi:10.1097/CJI.0b013e318177092b
104. Gottschalk S. Her2 and TGFBeta CTLs in treatment of Her2 positive malignancy (HERCREEM). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) (2009-2013). Available from: http://clinicaltrials.gov/ct2/show/NCT00889954?term=HERCREEM&rank=1
105. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids (2013) 2:e105. doi:10.1038/mtna.2013.32
106. Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, et al. Cancer concepts and principles: primer for the interventional oncologist-part I. J Vasc Interv Radiol (2013) 24(8):1157-64. doi:10.1016/j.jvir.2013.04.023
107. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 15(23):7412-20. doi:10.1158/1078-0432.CCR-09-1624
108. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 102(18):1388-97. doi:10.1093/jnci/djq310
109. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 39(1):49-60. doi:10.1016/j.immuni.2013.07.002
110. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 18(4):843-51. doi:10.1038/mt.2010.24